spacer
home > ebr > summer 2002 > a case for alternative financing in biomedical companies industry dynamics
PUBLICATIONS
European Biopharmaceutical Review

A Case for Alternative Financing in Biomedical Companies INDUSTRY DYNAMICS

The biomedical sector is gripped by the imminent threat, or promise, of consolidation. Many company founders and investors may lose their investments and the efforts of the last five years without a flexible response to the strains imposed on their current business plans. For some, the only alternative will be to restructure their business strategy and to adjust to the needs of the changing market conditions.In such challenging times, seeking an alternative approach to the traditional financing of biomedical businesses may be prudent. This article aims to review some of the better known choices for companies at each stage of development, and to introduce a new alternative approach which may be of vital interest in the future, particularly for those at a later stage of development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martin Austin, Director of European Operations, Paul Royalty Funds at Paul Capital Partners

Martin Austin is Director of European Operations at Paul Royalty Funds. Martin joined Paul Capital Partners in 2000 to lead the European activities for the Royalty Acquisition Fund in sourcing and due diligence. In 1988 he co-founded Machine Intelligence Technologies in the UK following over 25 years in the pharmaceutical industry with G. D. Searle and Synthйlabo, and as a Consultant with Marketing Improvements Ltd.
He then went on to found MHIG Ltd - a UK/German joint venture market research consultancy. In 1996 he joined F-Hoffmann-La Roche in Basel, Switzerland, becoming global Head of Business Development for Pharmaceuticals. Martin has an Advanced Certificate in Education from Reading University and a BA from the UK Open University.

spacer
Martin Austin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement